Serum free expansion and transduction of human Vγ9δ2 T cells for adoptive immunotherapy

Background and AimGamma delta T cells are multivalent immune cells with innate and adaptive features that sense a broad spectrum of tumor-associated stress patterns to lyse them without prior potentiation. They are therefore a good option for developing an off-the-shelf therapeutic immune cell product with antitumor functions. Therefore, we aimed to develop an optimized cGMP compatible protocol for expanding V gamma 9-V delta 2 T cells in a serum-free media for adoptive immunotherapy applications. Methods and ResultsPeripheral blood mononuclear cells (PBMC) from healthy donors were activated with Zoledronic Acid (ZOL) and IL-2 for 14 days. Cell proliferation, fold expansion, and phenotype were monitored. Among the regular donors, the baseline levels (day 0) of CD3+Vgamma9+delta2+ T cells were (05.10+/-0.74%). There was a robust expansion of V gamma 9-V delta 2 T cells in the serum-free media (110+/-29.89-fold). During processing, an abrupt reduction of {beta} T cells was observed as early as day +07. After two weeks, 87.82+/-5.11% (n=8) of T cells were CD3+Vgamma9+ in Optimizer with 97.15+/-0.7% of the CD3+Vgamma9+ T cells positive for delta2. The CD3+Vgamma9+ NKG2D+ increased during expansion, reaching 93.76+/-1.55% expression on day +14. V gamma 9-V delta 2 T cells expanded in the serum-free (Optimizer) media had relatively reduced variance and reduced over all yield and fold expansion but comparable percentage of Vgamma9+ and {beta} TCR+ T cells on day 14. A flow cytometry-based tumor-toxicity assay gauged the antitumor functions against K562 cell lines. Pretreatment of K562 cells with ZOL differentially enhanced (2.48+/-0.76 fold) the cytotoxic capacity of V gamma 9-V delta 2 T cells in a donor-dependent manner. The conditions for lentiviral transduction and transgene expressions of V gamma 9-V delta 2 T cells were improvised as gauged by GFP expression driven by CMV promoter (39.09+/- 8.94%) without compromising the viability. ConclusionWe have optimized a cGMP compatible protocol for expansion of human V gamma 9-V delta 2 T cells in a serum-free media with high purity and viability in as early as 07 days. Pretreatment of target tumor cells with ZOL enhanced the cytotoxicity, revealing the impact of V gamma 9-V delta 2 T cell intrinsic factors in tumor lysis. This protocol, may be scaled up for clinical translation for adoptive immunotherapy.